VERAXA Biotech AG was founded in May 2021 via a merger of two spin-offs from the European Molecular Biology Laboratory (EMBL) – Araxa Biosciences and Velabs Therapeutics. Both companies emerged from scientific discoveries made at EMBL and had complementary technologies and expertise.
VERAXA Biotech is listed on the Nasdaq Global Market under the symbol “VRXA”.
VERAXA Biotech principal executive offices are located at Talacker 35, CH-8001, Zurich, Switzerland. Its main R&D activities are located at its R&D hub at Im Neuenheimer Feld 584, 69120 Heidelberg, Germany.
December 31st
No, please contact a licensed stockbroker or use an online trading account.
- Quarterly, annual and other investor reports & materials can be found in the IR section of the corporate website under ‘SEC Filings’.
- All SEC filings can also be accessed directly from the SEC at www.sec.gov
- Since VERAXA Biotech began trading on NASDAQ on March xx, first reports will be published during the course of 2026. For more information on the timing of such publications, please refer to the events section of the corporate website or the IR section.
Grassi & Co. Certified Public Accountants, PC
Continental Stock Transfer & Trust Company
1 State Street — 30th Floor
New York New York 10004
https://continentalstock.com
Duane Morris LLP
Please reach out via ir@veraxa.com.
Please click on ‘Email Alerts’ under ‘Investor Resources’ in the IR section of the corporate website.